Abstract
Background Latin America’s diverse genetic makeup, shaped by centuries of admixture, presents a unique opportunity to study Alzheimer’s disease dementia (AD) and frontotemporal dementia (FTD). Our aim is to identify genetic variations associated with AD and FTD within this population.
Methods The Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat) recruited 2,162 participants with AD, FTD, and healthy controls from six Latin American countries (Argentina, Brazil, Chile, Colombia, Mexico, and Peru). All participants underwent array, exome, and/or whole-genome sequencing. Population structure was analyzed using Principal Component Analysis and ADMIXTURE, projecting the ReDLat population onto the 1000 Genomes Project database. To identify genes associated with autosomal dominant, autosomal recessive, or X-linked forms of adult-onset dementia, we searched the Online Mendelian Inheritance in Man database and analyzed pedigree information. Variant interpretation followed guidelines from the American College of Medical Genetics and Genomics, and the Guerreiro algorithm was applied for the PSEN1 and PSEN2 genes.
Results Global ancestry analysis of the ReDLat cohort revealed a predominant mix of American, African, and European ancestries. Uniquely, Brazil displayed an additional East Asian component accurately reflecting the historical admixture patterns from this region. We identified 17 pathogenic variants, a pathogenic C9orf72 expansion, and 44 variants of uncertain significance. Among our cohort, 70 families exhibited autosomal dominant inheritance of neurodegenerative diseases, with 48 families affected by AD and 22 by FTD. In families with AD, We discovered a novel variant in the PSEN1 gene, c.519G>T (p.Leu173Phe), along with other previously described variants seen in the region, such as c.356C>T (p.Thr119Ile). In families with FTD, the most commonly associated gene was GRN, followed by MAPT. Notably, we identified a patient meeting criteria for FTD who carried a pathogenic variant in SOD1, c.388G>A (p.Phe21Leu), which had previously been reported in another FTD patient from the same geographical region.
Conclusions This study provides the first snapshot of genetic contributors to AD and FTD in a multisite cohort across Latin America. It will be critical to evaluate the generalizability of genetic risk factors for AD and FTD across diverse ancestral backgrounds, considering distinct social determinants of health and accounting for modifiable risk factors that may influence disease risk and resilience across different cultures.
Competing Interest Statement
J.S.Y and K.S.K collaborate with the scientific advisory board of the Epstein Family Alzheimers Research Collaboration. C.J., M.A.N., H.L., D.V. and M.J.K. participation in this project was part of a competitive contract awarded to DataTecnica LLC by the National Institutes of Health to support open science research. M.A.N. also owns stock from Character Bio Inc and Neuron23 Inc
Funding Statement
This research was supported in part by the Intramural Research Program of the NIH, National Institute on Aging (NIA), National Institutes of Health, Department of Health and Human Services; project number Z1A AG000534 and AG000548, as well as the National Institute of Neurological Disorders and Stroke. ReDLat is supported by the Fogarty International Center; the National Institutes of Health, National Institute on Aging (R01 AG057234, R01 AG075775, R01 AG021051, R01 AG083799 and CARDS NIH); the Alzheimers Association (SG 20725707); the Rainwater Charitable foundation Tau Consortium; the Bluefield Project to Cure Frontotemporal Dementia; and the Global Brain Health Institute). J.AU. is supported by the Rainwater Charitable Foundation. A.I. A.I. is supported by ReDLat grants mentioned above and by ANID/FONDECYT Regular (1210195, 1210176 and 1220995); ANID/FONDAP/15150012; ANID/PIA/ANILLOS ACT210096; FONDEF ID20I10152 and ID22I10029; and ANID/FONDAP 15150012. A.S. is supported by ReDLat grants mentioned above and by ANID/FONDAP/15150012, ANID/FONDECYT Regular / 1231839 C.D.A. is supported by ANID/FONDECYT Regular 1210622, ANID/PIA/ANILLOS ACT210096. J.SY. receives funding from NIH NIA R01AG062588, R01AG057234, P30AG062422, P01AG019724, U19AG079774; NIH NINDS U54NS123985; NIH NIDA 75N95022C00031; the Rainwater Charitable Foundation; the AFTD Susan Marcus Memorial Fund; the Larry L. Hillblom Foundation; the Bluefield Project to Cure Frontotemporal Dementia; the Alzheimers Association; the Global Brain Health Institute; the French Foundation; the Mary Oakley Foundation; Alector, Transposon Therapeutics J.A.F. receives funding from NIH NIA R01 (US South American initiative for genetic neural behavioral interactions in human neurodegenerative research) / Alzheimers Association (AA) / Tau Consortium (TC) / Global Brain Health Institute (GBHI). The contents of this publication are solely the responsibility of the authors and do not represent the official views of these institutions. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of INECO-Centro de Psicologia Medica San Martin de Tours, Argentina (FWA00028264) gave ethical approval for this work. Ethics committee/IRB of Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo, Brazil (FWA00001035) gave ethical approval for this work. Ethics committee/IRB of Hospital Clinico Universidad de Chile, Chile (FWA00029089) gave ethical approval for this work. Ethics committee/IRB of Universidad Adolfo Ibanez, Chile (FWA00030846) gave ethical approval for this work. Ethics committee/IRB of Comite de Bioetica del Instituto de Investigaciones Medicas, Facultad de Medicina, Universidad de Antioquia, Colombia (FWA00028864) gave ethical approval for this work. Ethics committee/IRB of Pontificia Universidad Javeriana Hospital Universitario San Ignacio, Colombia (FWA00001113) gave ethical approval for this work. Ethics committee/IRB of Fundacion Valle de Lili, Colombia (FWA00029865) gave ethical approval for this work. Ethics committee/IRB of Instituto Nacional de Ciencias Medicas, Mexico (FWAA00014416) gave ethical approval for this work. Ethics committee/IRB of Hospital Nacional Docente Madre Nino San Bartolome, Peru (FWA00010121) gave ethical approval for this work. Ethics committee/IRB of University of California San Francisco-Memory and Aging Center, USA (FWA00000068) gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
↵† Passed away during the preparation of this manuscript on September 10, 2024
Data Availability
All the scripts used for the study have been compiled into a single GitHub repository: https://github.com/TauConsortium/redlat-genetics. Data from the present study is available upon request to the authors and the executive committee of the Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat)
List of abbreviations
- 1000GP:
- 1000 Genomes Project
- ACE-III:
- Addenbrooke’s Cognitive Examination-III
- ACMG:
- American College of Medical Genetics
- AD:
- Alzheimer’s disease
- AFR:
- African
- AF:
- Allelic frequency
- CDR:
- Clinical Dementia Rating Scale
- DNA:
- Deoxyribonucleic acid
- EDTA:
- Ethylenediaminetetraacetic acid
- EUR:
- European
- FTD:
- Frontotemporal dementia
- GIAB:
- Genome in a Bottle Consortium
- MoCA:
- Montreal Cognitive Assessment
- MMSE:
- Mini-Mental State Examination
- OMIM:
- Online Mendelian Inheritance in Men database
- PC:
- Principal component
- PCA:
- Principal component analysis
- PCR:
- Polymerase chain reaction
- QC:
- Quality control
- qPCA:
- Quantitative Polymerase chain reaction
- ReDLat:
- Multi-Partner Consortium to Expand Dementia Research in Latin America
- SNP:
- Single Nucleotide Polymorphism
- SNV:
- Single nucleotide variants
- VCF:
- Variant Call Format
- VUS:
- Variant of uncertain significance
- VQSR:
- Variant quality score recalibration
- WES:
- Whole exome sequencing
- WGS:
- Whole genome sequencing
